4//SEC Filing
Nolan Sean P. 4
Accession 0001415889-25-000599
CIK 0001806310other
Filed
Jan 2, 7:00 PM ET
Accepted
Jan 3, 5:38 PM ET
Size
8.7 KB
Accession
0001415889-25-000599
Insider Transaction Report
Form 4
Nolan Sean P.
DirectorChief Executive Officer
Transactions
- Award
Common Stock
2025-01-02+892,500→ 2,078,358 total - Award
Employee Stock Option (right to buy)
2025-01-02+892,500→ 892,500 totalExercise: $1.85Exp: 2035-01-02→ Common Stock (892,500 underlying)
Holdings
- 1,535,545(indirect: See footnote)
Common Stock
Footnotes (3)
- [F1]Represents a restricted stock unit ("RSU") award. The RSU grant was approved by the Issuer's compensation committee of the board of directors and will be effective as of the date the Issuer has an effective Registration Statement on Form S-8 registering the shares available for issuance under the 2020 Stock Incentive Plan. The RSUs will vest in four equal annual installments beginning on January 2, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.
- [F2]The securities are held by Nolan Capital, LLC (the "LLC"). The Reporting Person is the President of the LLC and has shared voting and investment power with respect to the shares held by the LLC.
- [F3]25% of the total number of shares underlying the option shall vest and become exercisable on January 2, 2026 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Documents
Issuer
Taysha Gene Therapies, Inc.
CIK 0001806310
Entity typeother
Related Parties
1- filerCIK 0001569926
Filing Metadata
- Form type
- 4
- Filed
- Jan 2, 7:00 PM ET
- Accepted
- Jan 3, 5:38 PM ET
- Size
- 8.7 KB